Skip to main content
OpenTrials
Completed

NCT Number: NCT03957759

Early Signs of Altitude Illness in Patients With COPD

This study evaluates whether structured self-monitoring (SSM) by a symptom checklist in combination with a pulse oximeter worn at the wrist allows lowlanders with COPD to accurately identify whether or not they will experience an altitude-related illness during altitude travel.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Obstructive Pulmonary Disease Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

National Center of Cardiology and Internal Medicine

Bishkek, Kyrgyzstan

About this study

This study evaluates whether structured self-monitoring (SSM) by a symptom checklist in combination with a pulse oximeter worn at the wrist allows lowlanders with COPD to accurately identify whether or not they will experience an altitude-related illness during altitude travel. After baseline evaluation at 760 m, patients will travel by bus within 3-5 h to the Tuja Ashu high altitude clinic at 3'100 m and stay there for 2 days. During this period, participants will perform SSM. They are instructed to report to study personnel if they fulfill predefined criteria for impeding altitude-related illness.

A planned interim analysis will be performed after the first year of the study or after completion of study by 80 participants, whichever comes first to allow any necessary adaptations of the sample size or terminate the study early for futility or high accuracy of the index test.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients, age 18-75 yrs.
  • COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 ≥92%, PaCO2 <6 kPa at 760 m.
  • Born, raised and currently living at low altitude (<800 m).
  • Written informed consent.

Exclusion criteria

  • COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1 <40% predicted; oxygen saturation on room air <92% or hypercapnia at 760 m).
  • Other lung disease or disorder of control of breathing
  • Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke, internal, neurologic, rheumatologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (>20 cigarettes per day)

Treatment and study plan

Structured self-monitoring during an altitude ascent and stay at high altitude

Diagnostic Test

Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).

Primary outcomes

  1. Diagnostic accurarcy measures of structured self-monitoring

    Time frame: Day 1 to 3 at 3100m

    Diagnostic performance includes sensitivity, specificity, positive and negative predictive values, and receiver operator curve area under the the curve. The diagnostic performance will be compared statistically using c-statistics against the reference test. Reference test will be the occurence of altitude-related illness defined as the following:

    • AMS defined by the Lake Louise questionnaire score or with AMSc score
    • severe hypoxemia (SpO2 <80% at rest >30 min; or SpO2 <75% at rest >15 min;
    • intercurrent illness that cannot be relieved by simple measures such as paracetamol 3x500 mg/day, inhalation of bronchodilators.
    • dyspnea or discomfort at rest requiring treatment with oxygen
    • chest pain or ECG signs of cardiac ischemia
    • severe hypertension: systolic blood pressure >200 mmHg, diastolic blood pressure >110 mmHg
    • new onset neurologic impairment
    • Any condition that requires study withdrawal according to the decision of the independent physician

Secondary outcomes

  1. Acute mountain sickness severity assessed by the Lake Louise score

    Time frame: Day 1 to 3 at 3100m

    The severity of acute mountain sickness will be assessed by the Lake Louise questionnaire. The severity will be calculated when the presence of headache and at least one of the following symptoms is present: gastrointestinal upset, fatigue or weakness and dizziness or lightheadedness. Each of the four questions is asked with the corresponding 0 to 3 rating of the response (0 = Not present, 1 = mild, 2 = moderate, 3 = severe). The sum of the responses on these questions is then calculated, resulting in the AMS severity.

  2. Altitude-related illness, incidence

    Time frame: Day 1 to 3 at 3100m

    Incidence of ARI during the stay at 3100 m.

    ARI is defined as the following:

    • AMS defined by the Lake Louise questionnaire score or with AMSc score
    • severe hypoxemia (SpO2 <80% at rest >30 min; or SpO2 <75% at rest >15 min;
    • intercurrent illness that cannot be relieved by simple measures such as paracetamol 3x500 mg/day, inhalation of bronchodilators.
    • dyspnea or discomfort at rest requiring treatment with oxygen
    • chest pain or ECG signs of cardiac ischemia
    • severe hypertension: systolic blood pressure >200 mmHg, diastolic blood pressure >110 mmHg
    • new onset neurologic impairment
    • Any condition that requires study withdrawal according to the decision of the independent physician

  3. Spirometric measurement of forced expiratory volume in one second

    Time frame: Day 2 at 760 and 3100m

    Altitude-induced change in the forced expiratory volume in one between 760 and 3100m

  4. Arterial partial pressure of oxygen

    Time frame: Day 2 at 760 and 3100m

    Altitude-induced change in arterial partial pressure of oxygen assessed by arterial blood gas puncture at 760 and 3100m

  5. Six-minute walk distance in meters

    Time frame: Day 2 at 760 and 3100m

    Altitude-induced change in the six-minute walk distance assessed by the six-minute walk test performed at 760 and 3100m

  6. Changes in ST-Segment of the ECG during ergometry

    Time frame: Day 1 at 760 and 3100m

    Altitude-induced change in the ST-Segment of the ECG assessed during a maximal ergometry test performed at 760 and 3100m

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Collaborators

  • National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

Registry information

Official study title

Self-Monitoring for Early Signs of Altitude Illness in Patients With Chronic Obstructive Pulmonary Disease. A Diagnostic Test Accuracy Study.

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
May 21, 2019
Registry last updated
Nov 29, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.